Gareth Sanger
Sanger, G.J.
VIAF ID: 270778021 (Personal)
Permalink: http://viaf.org/viaf/270778021
Preferred Forms
-
100 0 _
‡a
Gareth Sanger
-
100 1 _
‡a
Sanger, G. J.
-
100 1 _
‡a
Sanger, G. J.
-
100 1 0
‡a
Sanger, G. J.
-
100 1 _ ‡a Sanger, G.J.
4xx's: Alternate Name Forms (4)
Works
| Title | Sources |
|---|---|
| 5-hydroxtryptamine-3 receptor antagonists / edited by Francis D. King, Brian J. Jones, Gareth J. Sanger. |
|
| The Concise Guide to PHARMACOLOGY 2013/14: overview |
|
| Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro. |
|
| Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific Pde10A phosphodiesterase splice variants. |
|
| Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats |
|
| Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate. |
|
| Do 5-HT4 Receptors Mediate the Intestinal Secretory Response to 5-HT in Rat In-vivo? |
|
| Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret |
|
| The effect of sympathetic nerve stimulation on serum gastrin, gastric acid secretion and mucosal blood flow responses to meat extract stimulation in anaesthetized cats |
|
| Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function |
|
| The effects of SB 204070, a highly potent and selective 5-HT4 receptor antagonist, on guinea-pig distal colon. |
|
| Effects of the peripherally acting NK receptor antagonist, SB-235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats. |
|
| The effects of various peptides on human isolated gut muscle |
|
| The effects of various pharmacological agents on the metoclopramide-induced increase in cholinergic-mediated contractions of rat isolated forestomach |
|
| Emesis in anti-cancer treatment, 1993: |
|
| Endocannabinoids and the gastrointestinal tract: what are the key questions? |
|
| Evidence for the involvement of central 5-HT7 receptors in the micturition reflex in anaesthetized female rats |
|
| Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat |
|
| Ex vivo study of human visceral nociceptors |
|
| Farnesoid X receptor - a molecular predictor of weight loss after vertical sleeve gastrectomy? |
|
| Functional and in situ hybridization evidence that preganglionic sympathetic vasoconstrictor neurons express ghrelin receptors. |
|
| Functional brain networks and neuroanatomy underpinning nausea severity can predict nausea susceptibility using machine learning |
|
| GABA(B) receptor function in the ileum and urinary bladder of wildtype and GABA(B1) subunit null mice. |
|
| Gastrointestinal pharmacology: challenges ahead. |
|
| Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. |
|
| Ghrelin and Motilin Control Systems in GI Physiology and Therapeutics. |
|
| Ghrelin and motilin receptor agonists: time to introduce bias into drug design |
|
| GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility |
|
| The guinea-pig distal colon--a sensitive preparation for the investigation of 5-HT4 receptor-mediated contractions. |
|
| Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design |
|
| The hungry stomach: physiology, disease, and drug development opportunities. |
|
| Hypersensitivity and hyperreactivity in the irritable bowel syndrome: An opportunity for drug discovery. |
|
| The identification of and rationale for drugs which act at the motilin receptor. |
|
| Identification of differentially expressed genes in dorsal root ganglia following partial sciatic nerve injury |
|
| Increased defaecation caused by 5-HT4 receptor activation in the mouse. |
|
| Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924. |
|
| Increased plasma ghrelin following infliximab in Crohn's disease |
|
| Inhibition by tianeptine of neuronally mediated contractions in the rat isolated gastrointestinal tract |
|
| Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action |
|
| Intrinsic nerve circuits of the gastrointestinal tract: identification of drug targets. |
|
| Investigational drug therapies for the treatment of gastroparesis. |
|
| Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. |
|
| Metabolites of arachidonic acid formed by human gastrointestinal tissues and their actions on the muscle layers. |
|
| Modulation of peristalsis by NK3 receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised. |
|
| Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases. |
|
| N-[(1-Butyl-4-piperidinyl)methyl]-3,4- dihydro-2H-[1,3]oxazino[3,2-a]indole- 10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity |
|
| Nausea and the quest for the perfect anti-emetic |
|
| Nerve injury-associated kinase: a sterile 20-like protein kinase up-regulated in dorsal root ganglia in a rat model of neuropathic pain |
|
| Neuropharmacology of emesis induced by anti-cancer therapy. |
|
| New target profiling for gastrointestinal disorders: where are we going? |
|
| The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying |
|
| Pharmacological characterization of the vanilloid receptor in the rat dorsal spinal cord. |
|
| Pica—A model of nausea? Species differences in response to cisplatin |
|
| Pinane thromboxane A2 analogues are non-selective prostanoid antagonists in rat and human stomach muscle. |
|
| Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisation. |
|
| The prokinetic-like activity of ghrelin in rat isolated stomach is mediated via cholinergic and tachykininergic motor neurones. |
|
| Prokineticin-2, motilin, ghrelin and metoclopramide: prokinetic utility in mouse stomach and colon |
|
| Prolonged anti-emetic activity and 5-HT3-receptor antagonism by BRL 46470 in conscious ferrets. |
|
| The rabbit motilin receptor: molecular characterisation and pharmacology. |
|
| Regional differences in the responses to prostanoids of circular muscle from guinea-pig isolated intestine |
|
| Regionally dependent neuromuscular functions of motilin and 5-HT4receptors in human isolated esophageal body and gastric fundus |
|
| The relationship between gastric motility and nausea: gastric prokinetic agents as treatments |
|
| The Relationship Between Symptom Improvement and Gastric Emptying in the Treatment of Gastroparesis: Remember the Pharmacology |
|
| The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and GPR43 receptor activation |
|
| The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modelling |
|
| RQ-00201894: A motilin receptor agonist causing long-lasting facilitation of human gastric cholinergically-mediated contractions. |
|
| Secoverine hydrochloride is a muscarinic antagonist in human isolated gastrointestinal muscle and myometrium |
|
| Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). |
|
| Site-specific splice variation of the human P2X4 receptor |
|
| Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants |
|
| Synergy between 5-HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach |
|
| Thermal, But Not Mechanical, Nociceptive Behavior is Altered in the Zucker Diabetic Fatty Rat and Is Independent of Glycemic Status |
|
| Translating 5-HT receptor pharmacology. |
|
| The translational value of rodent gastrointestinal functions: a cautionary tale. |
|
| Treatment of nausea and vomiting: gaps in our knowledge. |
|
| The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression |
|
| UDP-glucose modulates gastric function through P2Y14 receptor-dependent and -independent mechanisms |
|
| Visually induced nausea causes characteristic changes in cerebral, autonomic and endocrine function in humans. |
|
